Race Oncology Limited (ASX:RAC – Get Free Report) insider Daniel Tillett acquired 62,631 shares of Race Oncology stock in a transaction that occurred on Wednesday, February 11th. The shares were purchased at an average cost of A$2.40 per share, with a total value of A$150,314.40.
Daniel Tillett also recently made the following trade(s):
- On Friday, February 13th, Daniel Tillett sold 14,000 shares of Race Oncology stock. The stock was sold at an average price of A$2.15, for a total value of A$30,100.00.
- On Thursday, January 22nd, Daniel Tillett purchased 400,000 shares of Race Oncology stock. The stock was purchased at an average cost of A$1.25 per share, with a total value of A$500,000.00.
- On Thursday, December 18th, Daniel Tillett bought 12,218 shares of Race Oncology stock. The stock was acquired at an average cost of A$2.58 per share, with a total value of A$31,534.66.
- On Thursday, December 18th, Daniel Tillett acquired 300,000 shares of Race Oncology stock. The stock was acquired at an average cost of A$1.25 per share, with a total value of A$375,000.00.
- On Wednesday, November 26th, Daniel Tillett bought 22,000 shares of Race Oncology stock. The shares were bought at an average price of A$2.67 per share, for a total transaction of A$58,740.00.
Race Oncology Price Performance
The stock has a market capitalization of $211.94 million, a price-to-earnings ratio of -14.60 and a beta of 1.74.
Race Oncology Company Profile
Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein).
Featured Articles
- Five stocks we like better than Race Oncology
- Energy Security Is Now National Security – Positioning Is Happening Now
- Gilder: Don’t Buy AI Stocks, Do This Instead
- 3 Signs You May Want to Switch Financial Advisors
- ATCX is Sitting on One of Brazil’s Largest Critical Minerals Portfolios!
- Why Q4 Could Destroy Your Wealth
Receive News & Ratings for Race Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Race Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
